CMS Open Payments · Program Year 2024
Aesculap Implant Systems, LLC
Aesculap Implant Systems, LLC reported $670,398.37 across General Payments, Research, and Ownership to 222 physicians and teaching hospitals across 222 transactions.
- $670.4K
- All-tracks total
- 222
- Transactions
- 222
- Recipients
- −$100.5K
- General Payments vs PY2023
Aesculap Implant Systems, LLC reported $670,398.37 across all CMS Open Payments tracks (General + Research + Ownership) to 222 physicians and teaching hospitals in Program Year 2024 - ranking #702 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $670,398.37, averaging $3.0K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aesculap-implant-systems-llc Aesculap Implant Systems, LLC
$670.4K · #702/1,925 · 0.0% industry · PY2024
- TOT $670.4K
- RANK #702
- SHARE 0.0%
- TXN 222
- RCP 222
- CAT 6
- GEN $670.4K
- ΔGEN −$100.5K
- TOP1 37.8%
- PY 2024
Volume peers
Nearest volume peer: Teleflex Incorporated ($670.6K)
Aesculap Implant Systems, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aesculap Implant Systems, LLC's CMS-reported General Payments decreased by $100.5K (−13.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AESCULAP IMPLANT SYSTEMS, LLCPY2023: AESCULAP IMPLANT SYSTEMS, LLCPY2024: Aesculap Implant Systems, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $770,939.06
- PY2024
- $670,398.37
What the Data Shows for Aesculap Implant Systems, LLC
$670,398.37: that is what Aesculap Implant Systems, LLC reported in payments to 222 physicians and teaching hospitals during Program Year 2024, spread across 222 transactions ($3.0K per transaction, $3.0K per recipient). The company sits at rank #702 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Royalty or License" leads the 6-category general-payment breakdown below at $352.6K (52.6% of General Payments, 17 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 6 types of general payments, Aesculap Implant Systems, LLC's largest category was "Royalty or License" at $352.6K - 52.6% of General Payments.
Aesculap Implant Systems, LLC reports 6 general-payment categories - the top three are Royalty or License (52.6%), Debt Forgiveness (29.5%), and Consulting Fee (12.4%). The remaining 3 categories make up 5.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Aesculap Implant Systems, LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $352.6K | 17 | 52.6% |
| Debt Forgiveness | $198.0K | 24 | 29.5% |
| Consulting Fee | $83.3K | 23 | 12.4% |
| Travel and Lodging | $22.5K | 71 | 3.4% |
| Space Rental or Facility Fees | $8.7K | 1 | 1.3% |
| Food and Beverage | $5.3K | 86 | 0.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $409,200.06 (61.0%) of $670,398.37 in this company's General Payments records across 81 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aesculap Implant Systems, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Roger Jackson
$253,265.19 across 4 reported transactions
- 2
Jeffrey Kozak
$50,653.92 across 4 reported transactions
- 3
Jack Zigler
$37,103.95 across 23 reported transactions
- 4
Northeast Georgia Medical Center
$36,292.00 across 1 reported transactions
- 5
Norman Regional Hospital Authority
$31,885.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aesculap Implant Systems, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aesculap Implant Systems, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aesculap Implant Systems, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Vascular Graft Solutions Inc
Verathon Inc.
Extremity Medical
Synapse Surgical LLC
Xtant Medical Inc
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.